Skip to main content
SpringerLink
Log in

Circulating free testosterone is an independent predictor of advanced disease in patients with clinically localized prostate cancer

  • Original Article
  • Published:
World Journal of Urology Aims and scope Submit manuscript

Abstract

Purpose

To evaluate the clinical value of the pre-treatment calculated free testosterone (fT), total testosterone (tT), sexual hormone-binding globulin (SHBG) and estradiol (E2) levels as potential predictors of pathological stage and grade in patients with clinically localized prostate cancer.

Methods

Preoperative sex hormone serum levels were prospectively measured in 137 patients who underwent radical prostatectomy at the University Hospital Ulm from February 2011 to February 2012. We related sex hormone levels to clinicopathologic data including tumour stage, Gleason score and prostate specific antigen (PSA). (Non)parametric statistical tests and receiver operating characteristics (ROC) analyses were performed.

Results

Preoperative serum fT levels were significantly associated with advanced disease (pT3–4 and/or pN+; p = 0.047) and lymph node involvement (pN+) (p = 0.027). Patients with low (<0.047 μg/l) vs. normal fT values (≥0.047 μg/l) were associated with higher tumour stage (p = 0.049), positive lymph node status (pN+ , p = 0.038) and advance disease (p = 0.016). Moreover, low tT values (≤0.193 μg/l; p = 0.018) and elevated SHBG levels (>48.4 nmol/l, p = 0.043) correlated with a higher Gleason score. Conversely, E2 levels were not associated with tumour stage or grade. Applying multivariate analysis, unlike tT, SHBG, and E2 levels, low fT levels were a significant independent predictor of advanced disease (relative hazard ratio 3.05, p = 0.028).

Conclusions

Low pre-treatment fT levels were significantly associated with tumour stage and extraprostatic tumour spread and might—in addition or combination with PSA—serve as a useful prognostic parameter for prostate cancer patients prior to radical prostatectomy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Morgentaler A, Traish AM (2009) Shifting the paradigm of testosterone and prostate cancer: the saturation model and the limits of androgen-dependent growth. Eur Urol 55:310–320

    Article  PubMed  Google Scholar 

  2. Sher DJ, Mantzoros C, Jacobus S, Regan MM, Lee GS, Oh WK (2009) Absence of relationship between steroid hormone levels and prostate cancer tumor grade. Urology 73:356–361

    Article  PubMed  Google Scholar 

  3. Solania A, Gallina A, Briganti A, Abdollah F, Suardi N, Capitanio U, Colombo R, Freschi M, Rigatti P, Montorsi F (2011) Preoperative hypogonadism is not an independent predictor of high-risk disease in patients undergoing radical prostatectomy. Cancer 117:3953–3962

    Article  Google Scholar 

  4. Ribeiro M, Ruff P, Falkson G (1997) Low serum testosterone and a younger age predict for poor outcome in metastatic prostate cancer. Am J Clin Oncol 20:605–608

    Article  PubMed  CAS  Google Scholar 

  5. Schatzl G, Madersbacher S, Thurridl T, Waldmüller J, Kramer G, Haitel A, Marberger M (2001) High-grade prostate cancer is associated with low serum testosterone levels. Prostate 47:52–58

    Article  PubMed  CAS  Google Scholar 

  6. Massengill JC, Sun L, Moul JW, Wu H, McLeod DG, Amling C, Lance R, Foley J, Sexton W, Kusuda L, Chung A, Soderdahl D, Donahue T (2003) Pretreatment total testosterone level predicts pathological stage in patients with localized prostate cancer treated with radical prostatectomy. J Urol 169:1670–1675

    Article  PubMed  Google Scholar 

  7. Lee SE, Chung JS, Han BK, Park CS, Moon KH, Byun SS, Choe G, Hong SK (2008) Preoperative serum sex hormone-binding globulin as a predictive marker for extraprostatic extension of tumor in patients with clinically localized prostate cancer. Eur Urol 54:1324–1332

    Article  PubMed  Google Scholar 

  8. Salonia A, Gallina A, Briganti A, Zanni G, Suardi N, Capitanio U, Colombo R, Bertini R, Freschi M, Guazzoni G, Rigatti P, Montorsi F (2011) Sex hormone-binding globulin is a significant predictor of extracapsular extension in men undergoing radical prostatectomy. BJU Int 107:1243–1249

    Article  PubMed  CAS  Google Scholar 

  9. Solania A, Briganti A, Gallina A et al (2009) Sex hormone-binding globulin: a novel marker for nodal metastases prediction in prostate cancer patients undergoing extended pelvic lymph node dissection. Urology 73:850–855

    Article  Google Scholar 

  10. Hoffman MA, DeWolf WC, Morgentaler A (2000) Is low serum free testosterone a marker for high grade prostate cancer? J Urol 163:824–827

    Article  PubMed  CAS  Google Scholar 

  11. Morote J, Ramirez C, Gomez E, Planas J, Raventos CX, de Torres IM, Catalan R (2009) The relationship between total and free serum testosterone and the risk of prostate cancer and tumour aggressiveness. BJU Int 104:486–489

    Article  PubMed  CAS  Google Scholar 

  12. Bonkhoff H, Berges R (2009) The evolving role of oestrogens and their receptors in the development and progression of prostate cancer. Eur Urol 55:533–542

    Article  PubMed  CAS  Google Scholar 

  13. Carruba G (2007) Estrogen and prostate cancer: an elipsed truth in an androgen-dominated scenario. J Cell Biochem 102:899–911

    Article  PubMed  CAS  Google Scholar 

  14. Solania A, Gallina A, Briganti A, Suardi N, Capitano U, Abdollah F, Bertini R, Freschi M, Rigatti P, Montorsi F (2011) Circulating estradiol, but not testosterone, is a significant predictor of high-grade prostate cancer in patients undergoing radical prostatectomy. Cancer 117:5029–5038

    Article  Google Scholar 

  15. Vermeulen A, Verdonck L, Kaufmann JM (1999) A critical evaluation of simple methods for the estimation of free testosterone in serum. J Clin Endocrinol Metab 84:3666–3672

    Article  PubMed  CAS  Google Scholar 

  16. Isom-Batz G, Bianco FJ Jr, Kattan MW, Mulhall JP, Lilja H, Eastham JA (2005) Testosterone as a predictor of pathological stage in clinically localized prostate cancer. J Urol 173:1935–1937

    Article  PubMed  CAS  Google Scholar 

  17. Imamoto T, Suzuki H, Fukasawa S, Shimbo M, Inahara M, Komiya A, Ueda T, Shiraishi T, Ichikawa T (2005) Pretreatment serum testosterone level as a predictive factor of pathological stage in localized prostate cancer patients treated with radical prostatectomy. Eur Urol 47:308–312

    Article  PubMed  CAS  Google Scholar 

  18. Teloken C, Da Ros CT, Weber FA, Cavalheiro AP, Graziottin TM (2005) Low serum testosterone levels are associated with positive surgical margins in radical retropubic prostatectomy: hypogonadism represents bad prognosis in prostate cancer. J Urol 174:2178–2180

    Article  PubMed  CAS  Google Scholar 

  19. Nishiyama T, Ikarashi T, Hashimoto Y, Suzuki K, Takahashi K (2006) Association between the dihydrotestosterone level in the prostate and prostate cancer aggressiveness using the Gleason score. J Urol 176:1387–1391

    Article  PubMed  CAS  Google Scholar 

  20. Zhang PL, Rosen S, Veeramachaneni R, Kao J, DeWolf WC, Bubley G (2002) Association between prostate cancer and serum testosterone levels. Prostate 53:179–182

    Article  PubMed  Google Scholar 

  21. Miller LR, Partin AW, Chan DW, Bruzek DJ, Dobs AS, Epstein JI, Walsh PC (1998) Influence of radical prostatectomy on serum hormone levels. J Urol 160:449

    Article  PubMed  CAS  Google Scholar 

Download references

Conflict of interest

The authors declare that they have no conflict of interest.

Author information

Authors and Affiliations

  1. Department of Urology, University Hospital Ulm, Prittwitzstrasse 43, 89075, Ulm, Germany

    Thomas Schnoeller, Florian Jentzmik, Ludwig Rinnab, Marcus V. Cronauer, Ilija Damjanoski, Friedemann Zengerling, Andreas Al Ghazal, Mark Schrader & Andres J. Schrader

Authors
  1. Thomas Schnoeller
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Florian Jentzmik
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ludwig Rinnab
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Marcus V. Cronauer
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Ilija Damjanoski
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Friedemann Zengerling
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Andreas Al Ghazal
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Mark Schrader
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Andres J. Schrader
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Florian Jentzmik.

Additional information

Thomas Schnoeller and Florian Jentzmik equally contributed to this work.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Schnoeller, T., Jentzmik, F., Rinnab, L. et al. Circulating free testosterone is an independent predictor of advanced disease in patients with clinically localized prostate cancer. World J Urol 31, 253–259 (2013). https://doi.org/10.1007/s00345-012-0902-5

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00345-012-0902-5

Keywords

Search

Navigation